Alexamorelin

Origin and Structure

Alexamorelin — sometimes referred to as GHRP-4 in older literature — is a synthetic peptide growth hormone secretagogue developed in the 1990s as part of the post-GHRP-6 wave of compounds attempting to refine the GHRP pharmacophore. It is a close structural relative of GHRP-6 and hexarelin, sharing the D-amino acid substitutions characteristic of the class that confer protease resistance and ghrelin-receptor binding.

Of the named compounds in this library, alexamorelin is among the most obscure. It received early pharmacodynamic characterization but never built a clinical development program, never reached a Phase 2 readout, and never acquired the research-tool status that sustained other early GHRPs. In the secondary literature it functions primarily as a footnote in discussions of the GHRP structure-activity relationship.

Mechanism of Action

Alexamorelin is an agonist at the ghrelin receptor (GHSR-1a) on pituitary somatotrophs, producing GH release through the same pathway exploited by every peptide in its class. Potency in the available pharmacodynamic work is moderate — comparable to GHRP-6, less than GHRP-2 or hexarelin. Like other first- and second-generation GHRPs, it produces measurable cortisol and prolactin release alongside GH, with the degree of "dirty" activation broadly similar to GHRP-6.

There is no evidence in the published literature that alexamorelin has any distinguishing non-GHSR mechanism — no CD36 activity, no unusual receptor selectivity, no pharmacokinetic advantage that differentiates it from other short-acting GHRPs.

Clinical Evidence

The clinical evidence base for alexamorelin is essentially absent:

• No completed Phase 2 trials. The compound was discontinued from active pharmaceutical development before advancing beyond early-phase pharmacodynamic characterization.
• No FDA or EMA filings. No regulatory agency has reviewed alexamorelin for any indication.
• Sparse peer-reviewed literature. Published work is concentrated in the 1990s and focused on receptor-binding and GH-release characterization, with almost no follow-up in the past two decades.

Anyone evaluating alexamorelin should recognize that its standing relative to the rest of the GHRP class is weaker than GHRP-2, GHRP-6, hexarelin, or ipamorelin — not because of safety concerns, but because of the absence of any meaningful clinical program that would have generated efficacy, selectivity, or long-term safety data.

Practical Considerations

Research-use protocols, where they exist, mirror the broader class: 100-200 mcg subcutaneously, two to three times daily, fasted. Cycling of 8-12 weeks followed by washout is the convention. However, the practical case for choosing alexamorelin over better-characterized alternatives is weak. For clean GH release without cortisol/prolactin elevation, ipamorelin is the reference compound. For maximum GH potency, GHRP-2 remains the class leader. For oral administration, MK-677 dominates. Alexamorelin's only realistic claim is historical — it is a compound that exists because the early GHRP structure-activity work explored many variants, most of which did not acquire distinctive niches.

Safety and Regulatory Status

Reported side effects in the limited available literature are typical for the class: transient flushing, injection-site reactions, appetite stimulation, cortisol and prolactin elevation, and mild headache. Long-term safety data does not exist in any meaningful form. The compound has not been studied in sufficiently large or long populations to rule out or confirm the subtle endocrine or metabolic concerns that occasionally surface with chronic GHRP exposure.

Alexamorelin is not FDA-approved for any indication, is not actively pursued by any pharmaceutical developer, and is captured by the WADA prohibited list (class S2) as a GH secretagogue. Supply is entirely through research-chemical vendors, and the relative obscurity of the compound means that product purity verification is more challenging than for well-established class members. For a broader perspective on how peptides in this category compare, see our recovery peptide guide and the ipamorelin reference page for the best-characterized clean GHRP.